This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Avanir Pharmaceuticals' CEO Presents At Canaccord Genuity 32nd Annual Growth Conference (Transcript)

Avanir Pharmaceuticals, Inc. (AVNR)

Canaccord Genuity 32nd Annual Growth Conference Call

August 14, 2012 9:30 AM ET


Keith Katkin – President and CEO


Ritu Baral – Canaccord Genuity


Ritu Baral

Good morning, everyone. Thanks for joining us. I'm Canaccord Genuity Senior Biotech Analyst, Ritu Baral, and thank you for joining us for the Avanir presentation. With us this morning to present is CEO, Keith Katkin.

As many of you know, Avanir has launched and is rolling out NUEDEXTA for pseudobulbar affect, a condition that affects many patients with neurodegenerative diseases such as stroke, traumatic brain injury and Alzheimer’s

Before we begin, I would just point you to the disclosures in your conference materials for the relationship between Canaccord on the banking front but without further ado, here's Keith.

Keith Katkin

Thanks, Ritu, and good morning, everyone. Thank you for joining us for the Avanir Incorporate presentation. I'd like to start with the forward-looking statement as I will be making statements that are forward-looking in nature. I would encourage everyone to look at our quarterly and annual filings available on either the SEC website or the Avanir website.

Avanir is a uniquely positioned specialty biopharmaceutical company focused on CNS therapies and I say uniquely positioned because we have accomplished arguably one of the more difficult aspects of a pharmaceutical company which is obtaining FDA approval of our lead product candidate, NUEDEXTA.

We obtained FDA approval late in 2010 as the first and only FDA-approved therapy for the treatment of pseudobulbar affect and subsequently launched NUEDEXTA in February, 2011.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs